FOLFIRINOX療法による構語障害に対するブチルスコポラミン臭化物の予防効果

抄録

A combination chemotherapy regimen comprising oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) is an approved treatment for unresectable pancreatic cancer and has a high therapeutic effect; however, it also has many side effects. One such undesirable side effect is dysarthria, which is believed to be caused due to the inhibition of cholinesterase by irinotecan. This study evaluates the prophylactic efficacy of scopolamine butylbromide for FOLFIRINOX-induced dysarthria. All patients who were administered FOLFIRINOX between March 1, 2014 and January 31, 2018 at the Japanese Red Cross Kyoto Daini Hospital were enrolled. Dysarthria developed in 9 (50％) out of 18 patients; these patients exhibited a high rate of apply to risk factors defined by the Japanese Society of Pancreatic Cancer (P = 0.018). Patients with dysarthria were given an oral dose of scopolamine butylbromide. None of the patients in whom scopolamine butylbromide was prophylactically administered experienced dysarthria in any of the treatment cycles; furthermore, no adverse events associated with scopolamine butylbromide use were observed in these patients. Our results show that scopolamine butylbromide may represent an option as a prophylactic agent for patients with FOLFIRINOX-induced dysarthria.